Figure 4.

Serum concentration profiles of PD-L1 antibodies and their variants in mice. Serum concentration profiles of (a) WT avelumab and its FcγR binding–deficient (N297A) and PD-L1 binding–deficient (R99K) variants, (b) WT avelumab and its low pI variant, and (c) WT atezolizumab and its FcγR binding–deficient variant (N297A). C57BL/6 mice were dosed with 200 µg of antibodies. Blood samples were collected at various time points, and serum concentrations were measured by immunoassay. Error bars represent standard deviations. FcγR, Fcγ receptor; PD-L1, programmed death ligand 1; pI, isoelectric point; WT, wild-type